Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Role of myeloid regulatory cells (MRCs) in maintaining tissue homeostasis and promoting tolerance in autoimmunity, inflammatory disease and transplantation

G. Amodio, J. Cichy, P. Conde, G. Matteoli, A. Moreau, J. Ochando, BH. Oral, M. Pekarova, EJ. Ryan, J. Roth, Y. Sohrabi, MC. Cuturi, S. Gregori,

. 2019 ; 68 (4) : 661-672. [pub] 20181024

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028134

Grantová podpora
BM1404 Mye-EUNITER COST Action
Project No: 114S354 TUBITAK
(#POR-2013-281) Irish Health Research Board
2011/02/A/NZ5/00337 Polish National Science Center
LTAUSA17160 Ministry of Education

Myeloid cells play a pivotal role in regulating innate and adaptive immune responses. In inflammation, autoimmunity, and after transplantation, myeloid cells have contrasting roles: on the one hand they initiate the immune response, promoting activation and expansion of effector T-cells, and on the other, they counter-regulate inflammation, maintain tissue homeostasis, and promote tolerance. The latter activities are mediated by several myeloid cells including polymorphonuclear neutrophils, macrophages, myeloid-derived suppressor cells, and dendritic cells. Since these cells have been associated with immune suppression and tolerance, they will be further referred to as myeloid regulatory cells (MRCs). In recent years, MRCs have emerged as a therapeutic target or have been regarded as a potential cellular therapeutic product for tolerance induction. However, several open questions must be addressed to enable the therapeutic application of MRCs including: how do they function at the site of inflammation, how to best target these cells to modulate their activities, and how to isolate or to generate pure populations for adoptive cell therapies. In this review, we will give an overview of the current knowledge on MRCs in inflammation, autoimmunity, and transplantation. We will discuss current strategies to target MRCs and to exploit their tolerogenic potential as a cell-based therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028134
003      
CZ-PrNML
005      
20190822083128.0
007      
ta
008      
190813s2019 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00262-018-2264-3 $2 doi
035    __
$a (PubMed)30357490
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Amodio, Giada $u San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), San Raffaele Scientific Institute IRCCS, Via Olgettina, 58, 20132, Milan, Italy.
245    10
$a Role of myeloid regulatory cells (MRCs) in maintaining tissue homeostasis and promoting tolerance in autoimmunity, inflammatory disease and transplantation / $c G. Amodio, J. Cichy, P. Conde, G. Matteoli, A. Moreau, J. Ochando, BH. Oral, M. Pekarova, EJ. Ryan, J. Roth, Y. Sohrabi, MC. Cuturi, S. Gregori,
520    9_
$a Myeloid cells play a pivotal role in regulating innate and adaptive immune responses. In inflammation, autoimmunity, and after transplantation, myeloid cells have contrasting roles: on the one hand they initiate the immune response, promoting activation and expansion of effector T-cells, and on the other, they counter-regulate inflammation, maintain tissue homeostasis, and promote tolerance. The latter activities are mediated by several myeloid cells including polymorphonuclear neutrophils, macrophages, myeloid-derived suppressor cells, and dendritic cells. Since these cells have been associated with immune suppression and tolerance, they will be further referred to as myeloid regulatory cells (MRCs). In recent years, MRCs have emerged as a therapeutic target or have been regarded as a potential cellular therapeutic product for tolerance induction. However, several open questions must be addressed to enable the therapeutic application of MRCs including: how do they function at the site of inflammation, how to best target these cells to modulate their activities, and how to isolate or to generate pure populations for adoptive cell therapies. In this review, we will give an overview of the current knowledge on MRCs in inflammation, autoimmunity, and transplantation. We will discuss current strategies to target MRCs and to exploit their tolerogenic potential as a cell-based therapy.
650    _2
$a zvířata $7 D000818
650    12
$a autoimunita $7 D015551
650    _2
$a biologické markery $7 D015415
650    _2
$a náchylnost k nemoci $7 D004198
650    12
$a homeostáza $7 D006706
650    _2
$a lidé $7 D006801
650    12
$a imunologická tolerance $7 D007108
650    _2
$a imunomodulace $7 D056747
650    _2
$a imunofenotypizace $7 D016130
650    _2
$a zánět $x etiologie $x metabolismus $7 D007249
650    _2
$a makrofágy $x imunologie $x metabolismus $7 D008264
650    _2
$a monocyty $x imunologie $x metabolismus $7 D009000
650    _2
$a myeloidní buňky $x imunologie $x metabolismus $7 D022423
650    _2
$a neutrofily $x imunologie $x metabolismus $7 D009504
650    _2
$a transplantace orgánů $7 D016377
650    _2
$a T-lymfocyty - podskupiny $x imunologie $x metabolismus $7 D016176
650    _2
$a homologní transplantace $7 D014184
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Cichy, Joanna $u Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland.
700    1_
$a Conde, Patricia $u Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Majadahonda, 28220, , Madrid, Spain.
700    1_
$a Matteoli, Gianluca $u Translational Research in Gastrointestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.
700    1_
$a Moreau, Aurélie $u Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France. Institut de Transplantation Urologie Nephrologie (ITUN), CHU Nantes, Nantes, France.
700    1_
$a Ochando, Jordi $u Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Majadahonda, 28220, , Madrid, Spain.
700    1_
$a Oral, Barbaros H $u Department of Immunology, Faculty of Medicine, Uludag University, Bursa, Turkey.
700    1_
$a Pekarova, Michaela $u Institute of Biophysics, The Czech Academy of Sciences, Brno, Czech Republic.
700    1_
$a Ryan, Elizabeth J $u Department of Biological Sciences, Faculty of Science and Engineering, University of Limerick, Limerick, Ireland.
700    1_
$a Roth, Johannes $u Institute of Immunology, University of Münster, Münster, Germany.
700    1_
$a Sohrabi, Yahya $u Molecular and Translational Cardiology, Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany.
700    1_
$a Cuturi, Maria-Cristina $u Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France. Institut de Transplantation Urologie Nephrologie (ITUN), CHU Nantes, Nantes, France.
700    1_
$a Gregori, Silvia $u San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), San Raffaele Scientific Institute IRCCS, Via Olgettina, 58, 20132, Milan, Italy. gregori.silvia@hsr.it.
773    0_
$w MED00001041 $t Cancer immunology, immunotherapy : CII $x 1432-0851 $g Roč. 68, č. 4 (2019), s. 661-672
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30357490 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190822083406 $b ABA008
999    __
$a ok $b bmc $g 1433283 $s 1066594
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 68 $c 4 $d 661-672 $e 20181024 $i 1432-0851 $m Cancer immunology and immunotherapy $n Cancer Immunol Immunother $x MED00001041
GRA    __
$a BM1404 Mye-EUNITER $p COST Action
GRA    __
$a Project No: 114S354 $p TUBITAK
GRA    __
$a (#POR-2013-281) $p Irish Health Research Board
GRA    __
$a 2011/02/A/NZ5/00337 $p Polish National Science Center
GRA    __
$a LTAUSA17160 $p Ministry of Education
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace